Bachem Rises on Technique for Producing Interferon: Zurich Mover

Bachem Holding AG (BANB) posted its biggest gain in a year after the Swiss maker of pharmaceutical ingredients said it found a simpler way to make a multiple sclerosis drug with a global market of more than $4 billion.

Bachem rose as much as 7.3 percent, the largest intraday gain since June 20 last year. The stock was 5.3 percent higher at 42 Swiss francs as of 11:17 a.m. in Zurich, the highest price in almost 20 months. More than 26,000 shares were traded, 10 times the three-month daily average.

Bachem worked with Kyoto, Japan-based GlyTech Inc. to develop a way to chemically synthesize interferon beta-1a, a naturally occurring human protein that helps to fight infection, the Bubendorf, Switzerland-based company said in a statement today. Biogen Idec Inc. (BIIB) earned $2.9 billion last year selling interferon beta-1a under the brand name Avonex, while Merck KGaA (MRK)’s Rebif garnered 1.9 billion euros ($2.4 billion). Both drugs are grown in Chinese hamster ovary cells.

The lab-produced version of the molecule is “as good or better” than the so-called recombinant versions, Bachem said. “Bachem and GlyTech with their know-how in peptide and carbohydrate chemistry are looking forward to a future partnership with a pharma or biotech company interested in conducting all further development studies through to market approval.”

To contact the reporter on this story: Simeon Bennett in Geneva at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.